TransCode Therapeutics share price logo

TransCode Therapeutics

NASDAQ: RNAZ

$1.73

+0.05

(+2.98%)

as on

TransCode Therapeutics Stock Performance

as on October 15, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $1.67
    $1.80
    downward going graph

    3.47%

    Downside

    4.05%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.52
    $15.90
    downward going graph

    12.14%

    Downside

    818.91%

    Upside

    downward going graph

TransCode Therapeutics share price movements today

Previous Close
$1.68
Open
$1.69
Volume
336.9K
Market Cap
$27.6M
Day's Low - High
$1.67 - $1.80
52 Week Low - High
$1.52 - $15.90

TransCode Therapeutics Historical Returns

1 Month Return
+ 1.82 %
3 Month Return
-80.42 %
1 Year Return
-88.24 %
3 Year Return
-99.99 %
5 Year Return
-100 %

TransCode Therapeutics Stock Fundamentals & Key Indicators

Check TransCode Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$27.6M

EPS (TTM)

-50.69

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.03

Industry PE ratio

-2.35

PEG Ratio

-0.00

EBITDA

-42.3M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-58.08%

TransCode Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of TransCode Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
TransCode Therapeutics image
TransCode Therapeutics
Buy$27.6M-100.00%-0.030.00%0.00%
Moderna image
Moderna
Neutral$85.3B-34.84%-28.20-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$128.5B166.75%29.4586.04%0.00%
Regeneron image
Regeneron
Buy$78.5B35.55%17.8384.86%0.49%

Stock Returns calculator for TransCode Therapeutics Stock including INR - Dollar returns

The TransCode Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

TransCode Therapeutics investment value today

Current value as on today

₹12,982

Returns

-₹87,018

(-87.02%)

Returns from TransCode Therapeutics Stock

-₹87,885 (-87.89%)

Dollar Impact

₹868 (+0.87%)

Analyst Recommendation on TransCode Therapeutics Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for TransCode Therapeutics. Average target price of $10

TransCode Therapeutics Share Price Target

Get share price movements and forecasts by analysts on TransCode Therapeutics.

What analysts predicted

82.7%UPSIDE

Target Price

$10

Current Price

$1.73

Analyzed by

7 Analysts

Target

$10.00

TransCode Therapeutics target price $10, a slight upside of 82.7% compared to current price of $1.73. According to 7 analysts rating.

Indian Investors' Interest in TransCode Therapeutics Stock

Search interest for TransCode Therapeutics Stock has increased by 42% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:42% versus previous 30 day period

TransCode Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
0
-
-
0
0
-
0
0
Operating Income
-3
-5
-2
-5
-3
-4
-4
-16
-7
-6
EBITDA
-3
-5
-2
-5
-12
-4
-4
-13
-17
-6
Interest Expense
0
0
0
0
0
-
0
0
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-3
-5
-2
-5
-12
-4
-4
-13
-17
-6
Income Tax Expense
-
-
-
-
-
-
-
0
0
0
Net Income
-3
-5
-2
-5
-12
-4
-4
-13
-17
-6
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

TransCode Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Mar 2024
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
0
0
0
0
-
Operating Income
0
0
0
-6
-18
-19
-15
-27
EBITDA
-
0
-1
-6
-17
-17
-16
-34
Interest Expense
-
0
0
0
17
0
0
0
Depreciation
0
-
-
0
0
0
0
0
Income Before Tax
0
0
-2
-6
-17
-18
-16
-34
Income Tax Expense
-
-
-
-
-
-
-
0
Net Income
0
0
-2
-6
-17
-18
-16
-34
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

TransCode Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-3
-5
-2
-5
-12
-4
-4
-1,369
-17,785
-6
Operating Cash Flow
-3
-2
-3
-3
-3
-4
-4
-8
-4,978
-5
Investing Cash Flow
0
0
0
0
-
-
-
0
-
-
Financing Cash Flow
6
0
2
7
8
-
0
23
-
0
Change in Cash
2
-1
-1
3
5
-4
-4
14
-4,978
-4

TransCode Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Mar 2024
Dec 2024
Dec 2025
Net Income
0
0
-2
-6
-17
-18
-16
-34
Operating Cash Flow
0
0
0
-5
-15
-18
-13
-19
Investing Cash Flow
-
-
-
0
0
0
0
0
Financing Cash Flow
0
0
1
25
0
15
16
31
Change in Cash
0
0
0
19
-15
-2
3
12

Global Institutional Holdings in TransCode Therapeutics

Check out the Institutions with significant holdings in TransCode Therapeutics.

Funds
Holdings
Fidelity Concord Street Trust
0.04%
VANGUARD INDEX FUNDS
0.04%
Vanguard
0.04%

TransCode Therapeutics News & Key Events

  • img

    Today's Timeline - 28 September

    Mon, 06:32 PM

    -

    TransCode Therapeutics reports promising Phase 1a results for TTX-MC138, showing 71.4% stable disease in patients with advanced solid tumors.

Insights on TransCode Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 723.8% return, outperforming this stock by 812.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 120.0% return, outperforming this stock by 220.0%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, RNAZ stock has moved down by -80.4%

About TransCode Therapeutics

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
OrganisationTransCode Therapeutics
Headquarters6 Liberty Square, Boston, MA, 02109, US
IndustryBiotechnology
CEOPhilippe Calais

Key Management of TransCode Therapeutics

Name

Title

Mr. John A. Tattory CPA

Interim Chief Financial Officer

Dr. Daniel R. Vlock M.D.

Chief Medical Officer

Dr. Michel Janicot PH.D.

Consulting Head of Translational Science

Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.

CEO & Executive Chairman of the Board

Dr. Zdravka Medarova Ph.D.

Scientific Co-Founder & Chief Scientific Officer

Dr. Anna Moore Ph.D.

Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board

FAQs

What is TransCode Therapeutics share price today?

TransCode Therapeutics share price today is $1.73 as on at the close of the market. TransCode Therapeutics share today touched a day high of $1.80 and a low of $1.67.

What is the 52 week high and 52 week low for TransCode Therapeutics share?

TransCode Therapeutics share touched a 52 week high of $15.90 on and a 52 week low of $1.52 on . TransCode Therapeutics stock price today i.e. is closed at $1.73,which is 89.12% down from its 52 week high and 13.82% up from its 52 week low.

What is TransCode Therapeutics's market capitalisation today?

TransCode Therapeutics market capitalisation is $0.00T as on .

How to invest in TransCode Therapeutics Stock (RNAZ) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for TransCode Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy TransCode Therapeutics Stock (RNAZ) from India?

Indian investors can start investing in TransCode Therapeutics (RNAZ) shares with as little as ₹95.13999938964844 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹951.40 in TransCode Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on TransCode Therapeutics share’s latest price of $1.73 as on October 15, 2026 at 1:29 am IST, you will get 5.7803 shares of TransCode Therapeutics. Learn more about fractional shares .

What are the returns that TransCode Therapeutics has given to Indian investors in the last 5 years?

TransCode Therapeutics stock has given -100% share price returns and 27.71% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?